MEI Pharma CEO Daniel Gold's 2021 pay jumps 31% to $2.9M
MEI Pharma reports 2021 executive compensation
By ExecPay News
Published: October 28, 2021
MEI Pharma reported fiscal year 2021 executive compensation information on October 28, 2021.
In 2021, five MEI Pharma executives received on average a compensation package of $1.6M, a 23% increase compared to previous year.
Average pay of disclosed executives at MEI Pharma
Daniel P. Gold, Chief Executive Officer, received $2.9M in total, which increased by 31% compared to 2020. 56% of Gold's compensation, or $1.6M, was in option awards. Gold also received $348K in non-equity incentive plan, $683K in salary, as well as $279K in stock awards.
David M. Urso, Chief Operating Officer, received a compensation package of $2.1M, which increased by 64% compared to previous year. 60% of the compensation package, or $1.3M, was in option awards.
Richard G. Ghalie, Chief Medical Officer, earned $1.1M in 2021.
Brian G. Drazba, Chief Financial Officer, received $1.1M in 2021, which increases by 12% compared to 2020.
Robert D. Mass, Chief Medical Officer, earned $724K in 2021, a 8% increase compared to previous year.
MEI Pharma's fiscal year ends on June 30.
Related executives
You may also like
Source: SEC filing on October 28, 2021.